Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 8% Following Insider Selling

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) dropped 8% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $24.50 and last traded at $23.9150. Approximately 71,215 shares traded hands during trading, a decline of 97% from the average daily volume of 2,503,471 shares. The stock had previously closed at $26.00.

Specifically, Director Richard A. Heyman sold 4,285 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $25.00, for a total value of $107,125.00. Following the completion of the transaction, the director owned 25,107 shares in the company, valued at $627,675. This trade represents a 14.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard A. Heyman sold 9,635 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $25.03, for a total transaction of $241,164.05. Following the completion of the transaction, the director owned 25,545 shares of the company’s stock, valued at approximately $639,391.35. This trade represents a 27.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In other news, insider Joseph P. Lyssikatos sold 91,198 shares of Enliven Therapeutics stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.22, for a total transaction of $2,482,409.56. Following the transaction, the insider owned 765,188 shares in the company, valued at approximately $20,828,417.36. The trade was a 10.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Analysts Set New Price Targets

Several research analysts recently issued reports on ELVN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $41.00.

Enliven Therapeutics Stock Performance

The business has a 50 day moving average price of $19.46 and a 200-day moving average price of $20.05. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -14.16 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. Quantbot Technologies LP increased its position in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares in the last quarter. AlphaQuest LLC acquired a new position in Enliven Therapeutics during the 3rd quarter worth approximately $96,000. Tower Research Capital LLC TRC boosted its holdings in Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after acquiring an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its stake in Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after acquiring an additional 2,500 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.